Fibronostics is a global diagnostics company, shaping the future of non-invasive diagnostics with artificial intelligence that provides algorithm-based solutions in a variety of diagnostic testing areas, focusing on screening, progression and prognosis of liver & kidney disease, and other chronic conditions. (HBV, HCV, NAFLD, NASH and ALD ).
The company is incorporated in Singapore & New York and is currently commercialized in North America, Asia, Europe and LATAM. Fibronostics is a SPRIM portfolio company with a pedigree in worldwide health innovation, research & consulting.
